Tirzepatide weight loss outcomes in PCOS

A new UK real-world study found similar average weight loss at 10 months among women prescribed tirzepatide for weight management who did and did not report polycystic ovary syndrome (PCOS). Among the small groups with 10-month data, women reporting PCOS lost a mean 19.40% of baseline weight, compared with 18.74% among women without PCOS. The difference was not statistically significant^[1]. That is useful evidence, but it does not make tirzepatide a proven treatment for PCOS itself.

The study is observational, PCOS status was self-reported, and only 40 women with PCOS had reached the 10-month visit. It answers a practical question about weight change in one digital service. It cannot establish that the medicine improves PCOS symptoms, fertility, or long-term health outcomes. For background on the medicine, see our tirzepatide guide.

What the study measured

Researchers conducted a retrospective open-cohort analysis of women aged 18 and over who were prescribed tirzepatide for weight management through a UK digital service between February 2024 and January 2025. Of 54,114 women in the overall cohort, 4,241, or 7.84%, reported PCOS. The researchers calculated percentage weight change at follow-up points and compared results by reported PCOS status^[1].

The headline comparison comes from the participants who had data at 10 months: 40 women with self-reported PCOS and 397 without it. The reported 95% confidence intervals were 16.42% to 22.38% weight loss for the PCOS group and 17.81% to 19.67% for the group without PCOS. Those intervals overlap, and the authors reported no significant difference between the groups^[1].

What the result suggests

PCOS can make weight management difficult, so the similar average results are notable. In this service, self-reported PCOS did not appear to prevent substantial weight loss among the people who remained in follow-up long enough to be measured. By 10 months, the estimated proportion of women with PCOS who had lost at least 20% of total body weight was 57.66%, with a 95% confidence interval of 47.44% to 68.29%^[1].

The paper also reported an association between engagement with the service's digital adjuncts and greater weight loss in the PCOS group. Women classified as digitally engaged lost 3.42 percentage points more weight at 10 months than those who were not, after the authors' analysis. This is an association within a non-randomized service, not proof that digital engagement caused the difference^[1].

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Its approved uses vary by jurisdiction. The US prescribing information lists chronic weight management and type 2 diabetes indications, rather than PCOS as an indication^[3]. Our tirzepatide regulation pages cover the country-specific context.

Why this does not settle treatment for PCOS

Weight change is not the same as treatment of a syndrome with reproductive, metabolic, and hormonal features. This paper did not test ovulation, menstrual regularity, androgen levels, pregnancy outcomes, or PCOS-specific quality of life as its main outcomes. It also did not randomly assign participants to tirzepatide or another approach. The authors describe the evidence for tirzepatide in women with PCOS as limited^[1].

The study's setting matters too. It reflects prescribing and follow-up in one commercial digital weight-management service, and the results may not carry over to every clinic or patient population. The published paper lists several authors with affiliations to Voy, the service involved in the research^[1]. That does not invalidate the findings, but it is relevant context when reading an observational analysis of a service's own users.

What we do not yet know

We do not yet know whether the similar 10-month weight-loss pattern would hold in a randomized PCOS-specific trial, across longer follow-up, or in people receiving care outside this service. We also do not know from this study whether tirzepatide changes the outcomes that many people with PCOS care about beyond weight. The small number of PCOS participants with 10-month data makes the estimate less precise than the overall cohort size may first suggest^[1].

There are practical safety questions that this analysis cannot answer. Tirzepatide is a prescription medicine, and its labeling includes contraindications, warnings, and adverse reactions that need individual clinical assessment^[3]. Readers considering weight-management options alongside PCOS can also review our PCOS and pregnancy planning explainer, which discusses why reproductive plans need to be part of that conversation.

How to read this result

The fairest reading is narrow: in this UK observational cohort, women who self-reported PCOS and reached 10 months of follow-up had weight-loss results that were not significantly different from women without reported PCOS. It is encouraging as a signal that PCOS did not obviously blunt outcomes in this setting. It is not a reason to assume the same result for every person, or to treat tirzepatide as a PCOS-specific therapy. Decisions about a prescription medicine, especially where pregnancy plans or other conditions are involved, belong with a qualified healthcare professional.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.